https://www.selleckchem.com/products/lgk-974.html
003) and PgR (p = 0.002) were associated with clinical benefit of PET at 6months, as opposed to progressive disease. High ER (p = 0.0023), PgR (p 0.001) and BCL-2 (p = 0.043) and low LKB1 (p = 0.022) were associated with longer time to progression. High PgR (p 0.001) and low MUC1 (p = 0.021) were associated with better BCSS. Expression of other biomarkers did not show any significant correlation. In addition to ER and PgR; MUC1, BCL-2 and LKB1 are important in determining the outcome of PET in this cohort. In addition to ER an
Like
Comment
Share
